Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine/Atropine for NMB Reversal in OSA
NCT02160223Phase 4Completed
- Sponsor
- Dışkapı Yıldırım Beyazıt Training and Research Hospital
- Start
- Jan 2012
- Primary completion
- Jun 2014
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by Dışkapı Yıldırım Beyazıt Training and Research Hospital. Primary endpoint: Time to Train-of-Four Ratio 0.9. Started Jan 2012; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT02160223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02160223.